New syringe design makes eye injection easier for doctors
NCT ID NCT07550504
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a pre-filled syringe of the medicine SB11 (a biosimilar to ranibizumab) is easy for eye doctors to use. Thirty adults with wet age-related macular degeneration, macular edema from retinal vein occlusion, or myopic choroidal neovascularization received one injection. The main goal was to see if doctors could successfully complete all 12 steps to prepare and give the injection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research site
Krakow, Poland
-
Research site
Olsztyn, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can a VR maze reveal hidden vision loss in macular degeneration?
- Can a new eye injection save vision in wet AMD?
- A new eye camera may spot stressed cells before vision loss begins
- A sharper look at the retina: new imaging technology may spot eye disease earlier
- Eye injection aims to tame leading causes of blindness